NPPA fixes Retail Prices of 36 Formulations: September 2022

Download the notification No. S.O. 4341(E) dated 15-09-2022

1005
NPPA Price of drugs
NPPA

Last Updated on September 20, 2022 by The Health Master

Download the notification No. S.O. 4341(E) dated 15-09-2022, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 36 drug formulations, vide notification No. S.O. 4341(E) dated 15-09-2022.

The notification reads as under:

In exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices
Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S.O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred to as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Note:
(a) The manufacturer of the above-mentioned formulations, i.e., “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is
payable to the Government on the retail price mentioned in column (6) of the above said
table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned
manufacturer in accordance with the retail price specified in column (6) of the above table.
per the provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer will issue
a price list in Form–V from the date of notification as per paragraph 24 of the DPCO, 2013 to
NPPA through IPDMS and submit a copy to the State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display a price list and the
supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of
on the premises where he carries on business in a manner so as to be easily accessible to any
a person wishing to consult it.

(e) The above-mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above, i.e., who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e., the Central
the Licensing Authority, as may be applicable, by the concerned manufacturer/marketing
companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned
manufacturer/marketing company shall be liable to deposit the overcharged amount along
with the interest thereon under the provisions of the DPCO, 2013 read with the Essential
Commodities Act, 1955.

(g) Consequent to the fixation of the retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Columns (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

High Court: Marketing Companies will have a right to the Trademark

Govt is in final stage to cap margins of key medicines

USFDA approves Terlipressin for injection to treat Kidney function 

PCI to amend Exit Examination Regulation for Diploma in Pharmacy

USFDA gives tentative approval for Sugammadex Injection

Drug alert: 45 out of 1330 samples declared as NSQ in August 2022

USFDA gives approval for Lenalidomide capsules

Panel recommends a separate legislation for Medical Devices

Govt adds 34 drugs in NLEM – National List of Essential Medicines

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news